Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02892149 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)
A Phase 3 study of Anemia and Dialysis-Dependent Chronic Kidney Disease, sponsored by Akebia Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,554
- Enrollment target
- 20
- Study locations
NCT02892149 is a Phase 3 study of Anemia and Dialysis-Dependent Chronic Kidney Disease that has completed, run by Akebia Therapeutics. The registered enrollment target is 3,554 participants, above the 378-participant average among 72 other Anemia trials with a reported enrollment target (840% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT02892149, a Phase 3 study of Anemia and Dialysis-Dependent Chronic Kidney Disease, has completed, sponsored by Akebia Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,554 participants
- Enrollment target
- 20
- Study locations
Study Summary
A multicenter, randomized, open-label, active-controlled Phase 3 study for the maintenance treatment of anemia in participants with dialysis-dependent chronic kidney disease (DD-CKD)
Conditions Studied
Interventions
- DRUG Vadadustat
- DRUG Darbepoetin alfa
Study Locations (20)
California
- Research Site - Anaheim
- Research Site #1 - Bakersfield
- Research Site #2 - Bakersfield
- Research Site - Canyon Country
- Research Site - Chula Vista
- Research Site - Downey
- Research Site - El Centro
- Research Site - Escondido
- Research Site - Fairfield
- Research Site - Glendale
- Research Site #1 - Granada Hills
- Research Site #2 - Granada Hills
- Research Site - La Habra
- Research Site - La Mesa
- Research Site - Lakewood
- Research Site - Long Beach
- Research Site - Long Beach
Alabama
- Research Site - Huntsville
Arizona
- Research Site - Mesa
Arkansas
- Research Site - Pine Bluff
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,554 participants |
| Start Date | 2016-08 |
| Est. Completion | 2020-03-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02892149
The ClinicalTrials.gov registry entry for NCT02892149 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,554 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 378-participant average among 72 other Anemia trials with a reported enrollment target (840% higher). The listed sponsor is Akebia Therapeutics, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Anemia appearing as the primary indexed condition, and to 2 interventions - of which Vadadustat is the first listed.
NCT02892149 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT02892149 about?
NCT02892149 is a clinical study titled "Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)". A multicenter, randomized, open-label, active-controlled Phase 3 study for the maintenance treatment of anemia in participants with dialysis-dependent chronic kidney disease (DD-CKD)
What is the current status of trial NCT02892149?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,554 participants. The study started on 2016-08. Estimated completion is 2020-03-30.
What conditions does trial NCT02892149 study?
This clinical trial studies the following conditions: Anemia, Dialysis-Dependent Chronic Kidney Disease.
What interventions are being tested in trial NCT02892149?
The interventions under investigation include: Vadadustat (DRUG), Darbepoetin alfa (DRUG).
Who is sponsoring clinical trial NCT02892149?
This trial is sponsored by Akebia Therapeutics, which has 24 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02892149 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
RECRUITING · Phase 3
-
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
ACTIVE NOT RECRUITING · Phase 3
-
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
ACTIVE NOT RECRUITING · Phase 3
-
INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections
ACTIVE NOT RECRUITING · Phase 3
-
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
ACTIVE NOT RECRUITING · Phase 3
-
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.